Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/57801
ADVERSE DRUG REACTIONS AFTER THE USE OF BENZNIDAZOLE IN BOLIVIAN PATIENTS WITH CHAGAS DISEASE
Benzonidazol
Reação adversa a medicamentos
Médicos sem Fronteiras
Author
Affilliation
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Médecins Sans Frontières. Operational Center. Barcelona (OCBA), Spain.
Médecins Sans Frontières. Operational Center. Barcelona (OCBA), Spain.
Médecins Sans Frontières. BRAMU (Brazilian Medical Unit). Médicos Sem Fronteiras. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
Médecins Sans Frontières. Operational Center. Barcelona (OCBA), Spain.
Médecins Sans Frontières. Operational Center. Barcelona (OCBA), Spain.
Médecins Sans Frontières. BRAMU (Brazilian Medical Unit). Médicos Sem Fronteiras. Rio de Janeiro, RJ, Brazil.
Abstract
Chagas disease remains an important problem in the world and there is an estimate of more than 10 million infected people worldwide. Benznidazole (BZN) is the main drug used for etiologic treatment of this disease. However, about 17 to 31% of patients discontinued the BZN treatment. The aim of the present study was to understand the predictors of BZN treatment discontinuation over time.
Female sex, older patients, those who lived in urban areas, patients who had had moderate or severe ADRs and those who had had skin disorders had a higher risk for BZN treatment discontinuation. For these patients, a close follow-up should be carried out, at regular intervals of at least once a week to monitor BZN treatment. Impact of study: The results of this study may help to identify patients of high risk for BZN treatment discontinuation. Also, these results suggest that a close follow-up by health professionals could be necessary in order to improve adherence and early detection of adverse drug reactions.
Keywords in Portuguese
Doença de ChagasBenzonidazol
Reação adversa a medicamentos
Médicos sem Fronteiras
Share